2 edition of Bioassay of ICRF-159 for possible carcinogenicity. found in the catalog.
Bioassay of ICRF-159 for possible carcinogenicity.
National Cancer Institute (U.S.). Division of Cancer Cause and Prevention.
by Dept. of Health, Education, and Welfare, Public Health Service, National Institutes of Health, National Cancer Institute, Division of Cancer Cause and Prevention, Carcinogenesis Testing Program in Bethesda, Md
Written in English
|Series||Carcinogenesis technical report series ; no. 78, DHEW publication ; no. (NIH) 78-1328, DHEW publication -- no. (NIH) 78-1328.|
|The Physical Object|
|Pagination||122 p. in various pagings :|
|Number of Pages||122|
African literature today
History Of The World (Teachers Resources: Reinforcement)
Review of Development.
A world of kindness
Baedeker of the Argentine Republic
The New-Year verses, of the printers lads, who carry the Pennsylvania gazette to the customers. January, 1758.
General report on the 1967 Wold Exhibition, Montreal, Canada.
Fifty-third chapter of Isaiah according to the Jewish interpreters.
Made in America
INDEX of possibilities
Bioassay of ICRF for possible carcinogenicity (OCoLC) Material Type: Government publication, National government publication: Document Type: Book: All Authors / Contributors: National Cancer Institute (U.S.).
Division of Cancer Cause and Prevention. OCLC Number: Notes: "CAS no. " Description. Additional Physical Format: Print version: National Cancer Institute (U.S.). Division of Cancer Cause and Prevention. Bioassay of ICRF for possible carcinogenicity. Bioassay of ICRF for possible carcinogenicity Published: () Bioassay of sulfisoxazole for possible carcinogenicity Published: () Bioassay of estradiol mustard for possible carcinogenicity Published: ().
Conducted for the Carcinogenesis Testing Program, National Cancer Institute, by Southern Research Institute, by Southern Research Institute, Birmingham, Ala.
NLM ID: [Book]. The NIH Library is a leading biomedical research library whose collection and services are developed to support the programs of the National Institutes of Health and selected U.S. Department of Health and Human Services (HHS) agencies.
This digitized collection of NIH Annual Reports is provided as. National Cancer Institute (d) Bioassay of ICRF for possible carcinogenicity. CAS no – NCI carcinogenesis technical report series no 78, DHEW publication no (NIH) 78–, Washington, DC Google ScholarCited by: 8.
In book: Genotoxic Impurities, pp Regulatory agencies currently rely on rodent carcinogenicity bioassay data to predict whether or not a.
The usefulness of mutagen-carcinogen correlations also depends on the quality of carcinogenicity data, and the statistical power to eliminate both false positives and false negatives. The quality of the Bioassay data was quite variable, often due to inconsistencies between experimental protocol and the established NCI by: 2.
I i t Bioassay of agents in mice Bioassay of agents in rats (n=) (n=55) i r 0 t I (n) 44 TABLE 12 7 CHEMICALS WERE CLASSED AS NON-ALERTING IN STRUCTURE (SA-) BUT INDUCED TUMOURS IN 3 OR MORE TISSUES IN THE RAT (cf.
TA THE SHADED % AND 25%) The Cited by: ORNL/EIS Contract No. Weng Information Division SCIENTIFIC RATIONALE FOR THE SELECTION OF TOXICITY TESTING METHODS: HUMAN HEALTH ASSESSMENT Robert H. Ross, John S. Drury, Michael G. Ryon, Mary L. Williams, John T. Ensminger, and M.
Virginia Cone Health and Environmental Studies Program Information Center Complex Work. InAmes and Gold described a conundrum of “too many carcinogens” among chemicals tested in rodent bioassays.
Their proposed nongenotoxic carcinogenic mechanism was amplification of the. draft survey and evaluation of in vitro toxicity test methods august prepared for office of toxic substances u.s. environmental protection agency washington, dc.
This banner text can have markup. web; books; video; audio; software; images; Toggle navigation. Why yet another volume in the series “Small Ring Compounds in Organic Synthesis” after five previous ones (Vol.). Well, small ring chemistry is still flourishing, and probably even more than ever, at least as far as the applications of small rings in Organic Synthesis are concerned.
However, it is possible to gain some selectivity of drug action, with consequent minimization of side-effects, by using receptorsubtype-selective p-adrenoceptor agonists.
Thus, pr adrenoceptor-selective agonists are more active on the heart, and p2-adrenoceptor-selective agonists are more active at most other sites in the body, including the.